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Introduction
This report is the third in a series of European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA)–Europol joint publications dedicated to prevalent illicit drugs. It focuses on 
amphetamine, a substance belonging to the family often referred to as amphetamine-type stimulants 
(ATS), which covers two main groups of substances: the ‘amphetamines’, which includes 
amphetamine, methamphetamine and related substances, and the ‘ecstasy-type’ drugs, which 
includes methylenedioxymethamphetamine (MDMA) and its close relatives 
methylenedioxyamphetamine (MDA) and methylenedioxyethylamphetamine (MDEA).
This study focuses on amphetamine production and markets in Europe, set in a global context. The 
first two EMCDDA–Europol joint publications were dedicated to methamphetamine and cocaine, 
while ecstasy-type substances, heroin and cannabis will be addressed in future publications.
The current patterns of amphetamine use in Europe are influenced by both historical and more 
recent factors. The use of amphetamine has evolved over the years since it was first synthesised, in 
1887. Originally an experimental substance used as a medicine to treat narcolepsy, amphetamine 
was used as a stimulant and performance enhancer by soldiers in the Second World War. In the 
late 1940s, it became a product of mass consumption, and it remained a widely prescribed 
medication well into the 1960s. Since the early 1970s, amphetamine has been an illicitly used and 
produced drug, and since the 1990s it has experienced renewed popularity in many parts of 
Europe, especially northern Europe.
Although, worldwide, methamphetamine is probably the most widely used synthetic stimulant, in Europe it 
is amphetamine, mostly in the form of the sulphate salt, that has historically been, and remains, the most 
produced, trafficked and used synthetic stimulant. Amphetamine, therefore, may be neatly viewed as a 
‘European drug’. Paradoxically, amphetamine has attracted much less attention in the European and 
global media, in policy circles and in academia than other drugs such as cannabis, cocaine or heroin. 
Even the closely related methamphetamine often seems to get more attention, although, compared with 
amphetamine, its production and use are much less prevalent in Europe. As a result, comparatively less 
information and analysis is available on amphetamine than on many other substances.
Even so, EMCDDA and Europol data and analysis, as well as the literature reviewed for this report, 
strongly suggest that the demand and supply of amphetamine in Europe are not secondary issues but 
warrant careful attention. Overall, amphetamine has stabilised as the second most widely used 
stimulant drug in Europe today, after cocaine. And in many countries, especially in the north and east 
of Europe, it is the most consumed stimulant, far ahead of cocaine. In fact, in many of those countries, 
amphetamine is the second most widely used illicit drug after cannabis. Broadly speaking, the 
European amphetamine market can be characterised by two main patterns of use. The biggest group 
of users are generally episodic or occasional users of the drug, most of whom will be relatively well 
integrated socially, especially in terms of housing and employment status. Patterns of use among this 
group will vary from occasional experimental use (only once or twice) to regular episodic but intensive 
periods of use. The typical mode of administration will be nasal insufflation (snorting) or oral ingestion 
(swallowing). A second, more chronic, pattern of use can also be found in some countries, notably 
Norway, Latvia, Sweden and the United Kingdom. This pattern of use is characterised by the chronic 
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(i.e. long-term) injection of often high-dose amphetamine. Users tend to be more socially marginalised 
and have more chronic health problems. In some countries, amphetamine therefore makes up a 
significant part of the national drug problem, with the concomitant health and social consequences, 
and the attendant costs to European societies, that this entails. 
Other consequences derive from the fact that the European amphetamine markets — 2 million 
Europeans are estimated to have used the drug in the last year — represent highly profitable 
‘business opportunities’ for organised crime. Although some amphetamine is produced in ‘kitchen-
type’ laboratories set up by chemistry students to supply a group of local friends, it is likely that the 
vast majority is manufactured in middling to large, sometimes ‘industrial size’, facilities. And, in this 
case, production and wholesale trafficking are in the hands of criminal organisations, some of 
which are able to operate throughout Europe, and even beyond, and which reap the corresponding 
profits. The decrease in the number of amphetamine production facilities dismantled in Europe in 
recent years does not necessarily make for comforting news, as forensic intelligence suggests that 
there is an increase in the production capacity of the facilities seized in key producer countries. The 
information available suggests that Europe is the world’s number one producer of amphetamine, 
with much of the production consumed within European borders. However, Europe also produces 
amphetamine that is usually exported to the Middle East and the Arabian Peninsula, where it is sold 
under the name ‘captagon’ (see p. 12). For conceptual clarity, the production and use of 
amphetamine in Europe needs to be distinguished from the production and export of amphetamine 
sold as captagon outside the European Union (EU). Patterns of use, including dose and route of 
administration, also are likely to differ considerably between these products. 
All this emphasises the need for careful monitoring of the production, trafficking and use of 
amphetamine in Europe today and is one of the reasons why the EMCDDA and Europol have 
joined efforts to publish the present report. Based on the latest statistical data, intelligence reports 
and original analysis, this joint publication hopes to enhance the understanding of amphetamine, 
an often overlooked but nevertheless key component on the European scene for stimulant drugs. 
Amphetamine powder in a clandestine facility at Calandsoog, the Netherlands, 
dismantled in 2011. Source: Europol, KLPD (Netherlands Police Agency) and LFO.
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Amphetamine
Amphetamine is a synthetic stimulant of the central nervous system, closely related to methamphetamine. 
Amphetamine is a member of the phenethylamine family, which includes a range of substances that may be 
stimulants, entactogens or hallucinogens. Thus, amphetamine is N,α-methylphenethylamine. Although 
amphetamine has occasional therapeutic uses in the treatment of narcolepsy and attention-deficit hyperactivity 
disorder, most is manufactured in clandestine facilities in Europe. 
The International Non-proprietary Name (INN) is amfetamine. Amfetamine is also the name required for the 
labelling of medicinal products within the EU. Other commonly used chemical names include 1-phenyl-2-
aminopropane and phenyliospropylamine, and hundreds of other synonyms and proprietary names exist (e.g. 
Benzedrine, Dexedrine). Amphetamine is sometimes included with methamphetamine and other less common 
substances (e.g. benzphetamine) under the generic heading ‘amphetamines’. English-language ‘street’ terms 
include speed, base and whizz. 
Amphetamine base is a colourless volatile oil, insoluble in water. The most common salt is the sulphate — a 
white or off-white powder that is soluble in water. Illicit products mostly consist of powders. Tablets containing 
amphetamine may carry logos similar to those seen on MDMA and other ecstasy tablets. Amphetamine may 
be ingested, snorted and, less commonly, injected. Unlike the hydrochloride salt of methamphetamine, 
amphetamine sulphate is insufficiently volatile to be smoked. When ingested, a dose may vary from several 
tens to several hundreds of milligrams depending on the purity. 
Amphetamine causes hypertension and tachycardia with feelings of increased confidence, sociability and 
energy. It suppresses appetite and fatigue and leads to insomnia. Following oral administration, the effects 
usually start within 30 minutes and last for many hours. Amphetamine is less potent than methamphetamine, 
but in uncontrolled situations, and when using the same route of administration, the effects are generally 
difficult to distinguish.
Acute intoxication causes serious cardiovascular disturbances as well as behavioural problems such as 
agitation, confusion, paranoia, impulsivity and violence. Chronic use of amphetamine causes neurochemical 
and neuroanatomical changes. Dependence — as shown by increased tolerance — results in deficits in 
memory, decision-making and verbal reasoning. Some of the symptoms resemble those of paranoid 
schizophrenia. Although these effects may outlast drug use, often they resolve eventually. Injection of 
amphetamine carries the same viral infection hazards [e.g. human immunodeficiency virus (HIV) and hepatitis] 
as are found with other injectable drugs such as heroin. Fatalities directly attributed to amphetamine are rare. 
The estimated minimum lethal dose in non-dependent adults is 200 mg.
Amphetamine is under international control. The R and S enantiomers (levamfetamine and dexamfetamine, 
respectively) as well as the racemate (a 50:50 mixture of the R and S stereoisomers) are listed in Schedule II 
of the United Nations 1971 Convention on Psychotropic Substances. The amphetamine precursors, 1-phenyl-
2-propanone (BMK, P2P), norephedrine and norpseudoephedrine, are listed in Table I of the United Nations 
1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. The corresponding EU 
legislation is set out in Council Regulation (EEC) No 3677/90 (as later amended), which governs trade 
between the EU and third countries.
Source: EMCDDA drug profiles.
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Amphetamine in Europe at a glance
Number of adults (15–64 years old) having used amphetamine in their lifetime: 12.5 million (3.8 %).
Number of young adults (15–34 years old) having used amphetamine during the last year: 1.5 million (1.1 %).
Amphetamines are reported as the primary drug in about 5 % of all treatment requests. 
Minimum of 34 500 seizures (1), resulting in the interception of an estimated  tonnes of amphetamine 
powder and 3 million amphetamine tablets (2). 
Countries reporting the largest number of seizures (in descending order): United Kingdom, Germany and 
Sweden. 
Countries reporting the largest quantities of amphetamines seized (in descending order): the Netherlands (3), 
United Kingdom, Germany, Turkey.
Mean retail price of amphetamine: ranges from EUR 8 to EUR 42 per gram. Since 2004, with the exception 
of the Netherlands, prices have declined or remained stable in all countries where data are available.
Mean purity of amphetamine: from 1 % to 29 % in most countries. Purity has declined since 2004 in all 
reporting countries, except Luxembourg, where it increased.
Source: EMCDDA 2011 Statistical bulletin (2009 data unless otherwise indicated) except (1) (source: Europol).
(1)  Number of amphetamine seizures: (a) In the absence of 2009 data from France, 2008 data were used to construct the 
European total. (b) The Netherlands is not included in the European total.
(2)  Quantities of amphetamine tablets seized: (a) Assuming an average weight of 250 mg per tablet, the number of amphetamine 
tablets seized in Europe would amount to an estimated 750 kg (this is not included in the 7.3 tonnes of amphetamine powder 
mentioned above). The amphetamine powders and amphetamine tablets seized in Europe rarely contain pure amphetamine; 
they are usually a mixture of amphetamine and other substances (adulterants). If adjusted for purity, quantities seized would 
probably be substantially lower. (b) Of the 3 million tablets seized, 94 % were seized by Turkey.
(3)  In the absence of 2008 and 2009 data for the Netherlands, data reported to Europol were used to construct European totals.
This report provides a condensed review of key issues relevant to understanding how Europe stands 
vis-à-vis the global amphetamine problem today. At various points in the document, background 
information on the chemistry of amphetamine, production methods and key European figures is 
provided.
Analysis begins with a summary of the history of amphetamine in Europe, set in a global context. 
There then follows an outline of the situation regarding current amphetamine trends worldwide, and 
recent changes in the international trafficking patterns of key precursor chemicals. 
The publication then focuses on Europe. The patterns and latest trends in the use, manufacture and 
trafficking of amphetamine in (and outside) Europe are examined, and significant information on 
European trends in precursor trafficking are summarised. Finally, the report provides an overview of 
initiatives at the European and international levels that address both amphetamine production and 
precursor trafficking, and the consequences of each.
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The global context
Historical background
Amphetamine was first synthesised in Berlin, Germany, in 1887 by the Romanian chemist Lazar 
Edeleano (Edeleano, 1887). However, it was not until the 1930s that the substance became 
acknowledged for its therapeutic value and properties (Remberg, 1997; Yoshida, 1997). In 1932, 
dl-amphetamine was marketed under the brand name ‘Benzedrine’ by the pharmaceutical firm 
Smith, Kline & French as a inhaler to treat nasal congestion in the United Kingdom. Later on, its 
stimulant effect was recognised and the drug was used to treat narcolepsy (ACMD, 2005). 
In the 1920s and 1930s, the medical and paramedical use of amphetamine increased in Europe 
and in the West in general. For instance, amphetamine was prescribed for depression and other 
mood disorders in the United Kingdom, or to treat obesity and asthma in the Netherlands (van Haal 
and Spruit, 1997), but it was also sought out for its stimulant effects (by students, for instance). In 
1938, in Sweden, advertisements for ‘pep pills’ based on amphetamine appeared in newspapers 
and on radio programmes aimed at different groups including housewives and students (Svensson, 
2009). 
During the Second World War, in the Allied camp, although millions of methamphetamine tablets 
were supplied to US military personnel (ACMD, 2005), the stimulant given to US soldiers was more 
commonly amphetamine (Zábranský, 2007). An estimated 72 million amphetamine tablets were 
supplied to British soldiers during the Second World War, while an estimated 200 million 
amphetamine and methamphetamine tablets were distributed to US troops (ACMD, 2005). 
Meanwhile, in Japan and Germany the stimulant distributed to military forces was 
methamphetamine (Heckmann, 1997; Suwaki et al., 1997). 
Fuelled by the sale of the huge war surplus of amphetamines to the general population, this initial 
wave of synthetic stimulant use continued into the late 1940s. There was widespread medical and 
non-medical use of amphetamine in Europe (especially in Sweden and the United Kingdom), 
amphetamine and methamphetamine in North America, and methamphetamine in the Far East 
(Tamura, 1989; UNODC, 2003; ACMD, 2005; Case, 2005; Zábranský, 2007). An estimated 
200 000 people were amphetamine users in Sweden in 1942–43, representing about 3 % of the 
adult population at the time. Of these, two-thirds were occasional users, some 60 000 used 
amphetamine between several times a year and twice a month, and approximately 4 000 used it 
every week (Svensson, 2009). 
Problematic side-effects of chronic and non-medical use of amphetamine, including hypertension, 
depression, dependence and psychiatric disturbances, have been documented since the late 1930s 
(ACMD, 2005). Nevertheless, amphetamine and methamphetamine were widely accepted as safe 
and helpful drugs by the medical profession and the public at large well into the 1960s. As 
accounts about negative side-effects and addiction emerged in the 1940s and 1950s, restrictions 
on the prescription and sale of amphetamine products (tablets, ampoules, inhalers) were imposed 
in Europe in the early 1950s, and sometimes earlier, as in Sweden in 1939 (Svensson, 2009). 
However, demand remained high and licit use of amphetamines continued in the 1950s and 
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1960s (Tamura, 1989; ACMD, 2005), especially among women (Case, 2005), and increasingly 
the drug became associated with various youth and counter cultures, including motorcycle gangs. 
The majority of the amphetamine available at that time was manufactured legally by 
pharmaceutical companies and prescribed by medical practitioners for a wide variety of disorders, 
including depression, attention-deficit disorder, alcoholism, obesity and anorexia (ACMD, 2005; 
Case, 2005; NDLERF, 2005). However, recreational use increased markedly among some 
subpopulations, for instance artists and young people, in several regions of Europe, and street 
dealing developed (Käll, 1997). The adoption by the United Nations of the International 
Convention on Psychotropic Substances in 1971 placed amphetamines under the same strict control 
measures as those applied to other illicit drugs such as heroin and cocaine (Yoshida, 1997). 
After enhanced international and national controls were imposed, supply channels began to shift in 
Europe during the 1960s and illicit sources of supply gradually emerged (ACMD, 2005). New 
illicit supply channels are reported to have taken three forms — illegal distribution or diversion of 
domestically manufactured pharmaceutical products; illegal importation of products manufactured 
abroad; and illicit domestic manufacture (Tamura, 1989; Käll, 1997; ODCCP, 2001; ACMD, 
2005; Case, 2005). 
In Europe, the United Kingdom experienced increasing misuse of amphetamine. From the 1950s, 
amphetamine obtained from licit medical prescription was diverted into the illicit market. By the 
1960s, this trend reached epidemic proportions in some cities. Over time, amphetamine and 
methamphetamine diverted from therapeutic use were replaced on the market by illicitly produced 
amphetamine sulphate (ACMD, 2005). In Sweden, amphetamine use continued to spread in the 
1960s, and the National Medical Board estimated that there were about 1 000 intravenous 
amphetamine users in the country in 1960 (Svensson, 2009). 
In the 1980s, control measures and the arrival of heroin to the European drug market seemed to 
cause the use of amphetamine to fall among most of western Europe’s problem drug users, although 
amphetamine remained popular in Scandinavia (EMCDDA, 2010a). Recreational amphetamine 
use was associated with the ‘punk rock’ subculture in the 1980s, and prevalence rose again in the 
1990s with the emergence of the electronic music scene, but problem amphetamine use remained 
low. Indications of the increased use of amphetamines first appeared in Poland and the Baltic states 
in the 1990s, and have been slowly increasing since then. Towards the late 1990s, northern 
European countries saw a new wave of amphetamine use, and problem amphetamine users 
outnumbered problem opioid users. However, in southern Europe, amphetamine has never been 
among the most popular or prevalent drugs. 
In summary, for a considerable period of time amphetamine was the most commonly available and 
used stimulant drug in Europe. This situation changed only with the introduction of widespread 
MDMA use in the 1990s, and with significant volumes of cocaine entering the European market in 
the last decade. Despite this, however, in most European countries amphetamine use remains an 
important element in patterns of stimulant use found today. In contrast to the global picture, 
methamphetamine is far less commonly seen in Europe. Although methamphetamine has been an 
important element of the drug problem in the Czech Republic since the 1970s, more recently 
methamphetamine use has also become more common in Slovakia, and very recently appears, to 
some extent, to be displacing amphetamine use in some Nordic and Baltic countries.
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Global situation
The production of illicit amphetamine-type stimulants may be seen as a lucrative business by many 
criminal actors. The main reason is that they can be produced almost anywhere at a relatively low 
cost, and that in general they are manufactured close to consumer markets, so that trafficking 
remains intra-regional, thereby reducing the additional risks of detection associated with cross-
border trafficking. The methods involved in the production of this drug are relatively simple and do 
not require those involved to have a high degree of expertise in organic chemistry. However, more 
problematic, from the perspective of an illicit producer, is that the precursor chemicals required for 
amphetamine production are often difficult to obtain. This has resulted in a global market for 
trafficking precursor chemicals required for amphetamine production. Some of the equipment used 
to manufacture amphetamine in Europe, especially in larger facilities, is fairly sophisticated and 
may be custom-made by specialist ‘facilitators’. The benefits gained from selling the final product 
amply cover the initial investment (UNODC, 2003, 2008a, 2009), with reported mark-ups 
between wholesale and retail prices of up to 300 % in the case of amphetamine (UNODC, 
2008b). Finally, in comparison with the production of most other types of illicit drugs, ATS 
production has the advantage of being relatively non-labour intensive (NDLERF, 2005) and can be 
carried out indoors, which means that production is not influenced by weather conditions and that it 
is much less exposed to law enforcement detection. 
Data and sources
Systematic and routine information to describe illicit drug markets and trafficking is still limited. Drug seizures 
are often considered as an indirect indicator of the supply, trafficking routes and availability of drugs; 
however, they also reflect law enforcement priorities, resources and strategies, the vulnerability of traffickers 
and reporting practices. Data on purity or potency and retail prices of illicit drugs may also be analysed in 
order to understand retail drug markets. However, the availability of these types of data may be limited and 
there may be questions of reliability and comparability. Intelligence information from law enforcement 
agencies may help complete the picture. The EMCDDA collects national data on drug seizures, purity and 
retail prices in Europe. Other data on drug supply come largely from the United Nations Office on Drugs and 
Crime (UNODC)’s information systems and analyses, complemented by additional information from Europol. 
Information on drug precursors can be obtained from the International Narcotics Control Board (INCB), 
European Commission, European Anti-Fraud Office (OLAF) and Europol, which are involved in international 
initiatives to prevent the diversion of precursor chemicals used in the manufacture of illicit drugs. These 
information sources are not always concordant, and currently work is under way to improve the compatibility, 
quality and comparability of data in this area. As many parts of the world lack sophisticated information 
systems related to drug supply, some of the estimates and other data reported, though representing the best 
approximations available, must be interpreted with caution.
Since the 1990s, the manufacture of amphetamines has been spreading globally with an 
increasing number of countries reporting production on their territory. Owing to a general lack of 
data on production and consumption of these drugs, estimating the amounts available for 
consumption is a challenge. The most recent estimates from the UNODC (2010) place the number 
of past-year users of amphetamines at between 14 and 53 million and potential global manufacture 
at between 160 and 600 tonnes in 2008. The UNODC does not distinguish between amphetamine 
and methamphetamine, but based on the estimates produced for 2006 (UNODC, 2008b), and 
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assuming stable market shares between amphetamine and methamphetamine since then, one-third 
of this potentially manufactured amount could be of amphetamine. 
Amphetamine is still produced mainly in Europe, with large-scale production and organised crime 
involvement being found principally in the north-western parts of the region, whereas small- to 
middle-scale production predominates in eastern Europe (Europol, 2007a; EMCDDA, 2009a) (1). In 
2008, 80 % of the amphetamine production facilities dismantled worldwide were in western and 
central Europe (UNODC, 2010). 
During the last 30 years, consumption of amphetamine tablets with a ‘captagon’ logo (2), a 
counterfeit pharmaceutical product, has spread from south-east Europe to the Near and Middle 
East, and there are several indications that illicit manufacture has also recently shifted to these 
areas. This displacement might be correlated with recent developments in production of other ATS: 
when production is an organised crime activity, the location of production is increasingly shifted 
from developed to developing countries, presumably to make use of the vulnerabilities of poorer 
countries, which often lack the resources to combat this phenomenon effectively. Other reasons for 
such shifts in location may include avoiding control and detection by using precursor chemicals not 
under control and diversification of trafficking routes (UNODC, 2009).
Data on laboratories dismantled worldwide since 2003 show that manufacture of amphetamine 
also occurs outside Europe, in particular in the United States and Australia, but also in Canada, 
Mexico, South Africa, Indonesia, India and Lebanon (as captagon). 
The chemical 1-phenyl-2-propanone (P2P, BMK) is a precursor predominantly used to manufacture 
amphetamine in Europe, but which may also be used to make methamphetamine (EMCDDA, 
2009b). BMK is placed under international control; it is listed in Table I of the United Nations 1988 
Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. International trade 
in BMK, licit uses of which include the manufacture of pesticides and cleaning agents, is relatively 
small and restricted to a few countries. In 2010, a total of 35 shipments of BMK were notified to 
the INCB, with eight countries exporting nearly 15 000 litres to 16 importing countries (INCB, 
2011). Global seizures of illicit BMK shipments decreased from 5 620 litres in 2008 to 4 900 litres 
in 2009. By comparison, the largest annual total of BMK seized internationally during the 2000s 
amounted to 18 238 litres and was reported to the INCB by the Netherlands in 2001 (INCB, 
2003). Seizures of BMK in Europe, including Russia, remained relatively stable in 2009, amounting 
to 2 483 litres, compared with 2 757 litres in 2008. In 2008 and 2009, two countries, China and 
Russia, confiscated almost all of the BMK seized worldwide (INCB, 2011). Information submitted to 
Europol in 2010 indicates that more than 11 tonnes of BMK was seized worldwide, including more 
than 5 tonnes intercepted in Belgium, and two seizures totalling more than 6 tonnes of BMK were 
made in Canada.
(1)  Methamphetamine (known as ‘pervitin’) predominates in the Czech Republic and, to some extent, in neighbouring 
countries, although recent reports note its possible spread outside this traditional area of production and 
consumption (EMCDDA, 2009b).
(2)  The composition of captagon tablets remains unclear; laboratory analyses, however, indicate that it no longer 
contains phenetylline (as opposed to the legitimately marketed captagon tablets that initially shaped the ATS 
market in the region), but amphetamine in combination with caffeine and other substances (UNODC, 2008b).
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Norephedrine is another precursor chemical that may be used to manufacture amphetamine, and is 
placed under international control in Table I of the 1988 UN convention. Global seizures of this 
precursor have been low in recent years, with 230 kg and 195 kg seized in 2008 and 2009, 
respectively, well below the 1.15 tonnes seized in 2007 (INCB, 2011). The vast majority of the 
norephedrine seized globally in 2009 was confiscated in the Netherlands (165 kg). 
Seizures of phenylacetic acid, a precursor of BMK (see below), rose sharply in 2009, with a total 
of almost 42 tonnes confiscated worldwide (INCB, 2011). This is far higher than the 160 kg or so 
seized worldwide in 2007 and again in 2008, or the 520 kg intercepted in 2006, but still below 
the exceptional 48 tonnes confiscated in 2005. The two countries seizing the most phenylacetic 
acid in 2009 (as in 2005) were China and Mexico. Phenylacetic acid seizures in Europe in 2009 
totalled 2.2 tonnes, most of which was recovered in Serbia (1.9 tonnes) and France (250 kg) 
(INCB, 2011). Phenylacetic acid was rescheduled from Table II to Table I of the 1988 UN 
convention in January 2011 (see below). 
Globally, amphetamine seizures increased almost eight fold in 10 years, from 3.1 tonnes in 1999 
to 24.3 tonnes in 2008 (UNODC, 2010). The proportion of total ATS seized accounted for by 
amphetamine also increased, from 8 % in 1999 to 47 % in 2008. These increases are largely 
attributable to large increases in seizures reported by a few countries in the Near and Middle East 
since 2004. Countries in this region accounted for about two-thirds of the quantity of amphetamine 
seized worldwide in 2008; one-third was reported by Europe, mostly western Europe, and 
negligible quantities were intercepted in the rest of the world (UNODC, 2010). 
Caution is required here as it is likely that awareness of amphetamine production and trafficking is 
particularly high in these two regions, which therefore are better equipped to identify seizures of 
amphetamine than some countries in other parts of the world where, because methamphetamine is 
traditionally believed to be the predominant substance, information systems are not adapted to 
identify and track amphetamine separately and seizures are usually combined with seizures of 
methamphetamine. Note that the reverse might be true in the case of a few countries in Europe 
which report amphetamine and methamphetamine seizures together, although in this case 
methamphetamine is believed to represent a negligible proportion of the total amount reported.
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Amphetamine production and precursors issues
The production process
The production of amphetamine sulphate is a multi-step chemical process involving a precursor 
chemical and a range of reagents and solvents. The main amphetamine precursor is benzyl methyl 
ketone (BMK), also known as 1-phenyl-2-propanone (P2P) or as phenylacetone, which may also be 
used to manufacture methamphetamine (EMCDDA, 2009b). BMK is usually a colourless or slightly 
yellow oily liquid, although some illicitly manufactured BMK may vary from yellow to dark brown 
(UNODC, 2005). In theory, 1 litre of BMK yields about 1.4 kg of amphetamine sulphate, but, in 
practice, yields in clandestine facilities have tended to be lower, usually well under 1 kg, owing to 
losses during the production process. The reagent chemicals used in the manufacture of 
amphetamine, such as formamide, ammonium formate and sulphuric and hydrochloric acids, 
facilitate a reaction, without becoming part of the final product. Solvents, for instance methanol or 
acetone, are used for dissolving a solid substance while maintaining the chemical composition 
(Krawczyk et al., 2009; NDLERF, 2005). 
Several methods can be used to manufacture amphetamine. They include the nitropropene route 
from benzaldehyde and nitroethane, the reductive amination method using aluminium amalgam 
and the reductive amination method at elevated pressure with the use of a Raney nickel catalyst. 
However, the most frequently used method in Europe is the so-called ‘Leuckart’ synthesis using BMK, 
which, despite its low yield, is arguably the easiest method to learn and put into practice (Europol, 
2010a). 
The facilities synthesising amphetamine illegally that have been dismantled in Europe vary in size 
from small ‘kitchen’ laboratories to extensive ‘online’ production facilities (Europol, 2010a). A 
range of equipment is needed for the production process. Depending on the scale of production, 
such equipment can include glass reaction vessels, reflux condenser tubes, electric heating mantles 
or gas burners, boiling stones, separation funnels, steam distillation equipment, vacuum pump 
facilities and glassware items. In the case of large-scale production, mostly occurring in the 
Netherlands and Belgium, it is increasingly common to find the use of ‘custom-made’ and industrial 
equipment, such as stainless steel reaction vessels and condenser tubes, refluxers, distillation 
machines and separator apparatus. Use of industrial equipment may increase the production 
capacity and subsequent yield from around 5–8 kg to up to 30–40 kg of end product per 
production batch, with no change in the overall production time of 20–30 hours using the Leuckart 
method (NDLERF, 2005; Europol, 2010a). In Poland, the capacity of clandestine amphetamine 
manufacturing facilities is also reported to have increased in recent years, from approximately 3 kg 
per production batch to between 4 and 8 kg. This is achieved by using larger steel reaction vessels 
of capacity 30–50 litres rather than the 20-litre glass reaction vessels formerly used (Krawczyk et 
al., 2009). 
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Steel reaction vessel of 120 litres capacity used in the 
clandestine production of amphetamine in a facility 
dismantled in Loosdrecht, the Netherlands (2003).
Source: KLPD, the Netherlands.
Reaction vessels of 20 litres (left) and 50 litres (right) capacity used in the distillation process in dismantled clandestine 
amphetamine production facilities at Kobyłka (2002) and Puchały (2008), respectively, both in Poland.  
Source: Central Bureau of Investigation, National Police Headquarters, Warsaw.
Clandestine amphetamine laboratories may pose significant risk of fire, explosion and toxic fume 
effects to those operating them and those nearby, and to law enforcement personnel when they 
enter them. There are also environmental threats linked to the chemical waste products generated 
during the production process (ranging from 18 to 24 kg of chemicals per 1 kg of amphetamine 
manufactured), and which can result in environmental hazards, pollution and physical harm 
depending on the method of disposal (ACMD, 2005; NDLERF, 2005).
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The precursors
BMK — properties, production and trafficking issues
The illicit production of key amphetamine precursors was rare in Europe until 2010. The processes 
require chemical knowledge and financial investment, as well as access to (non-scheduled) 
chemicals and equipment. However, although importations of BMK into Europe continue, recent 
intelligence collected by Europol suggests that some of the BMK used by criminal groups is now 
self-produced in Europe (Europol, 2011a).
Supply and/or importation problems due to enhanced international cooperation and law 
enforcement can lead to the illicit manufacture of precursors within Europe using so-called ‘pre-
precursors’ such as phenylacetic acid, benzaldehyde or, more recently, alpha-
phenylacetoacetonitrile (APAAN). For instance, Europol reports several large seizures of APAAN 
consignments and the dismantlement of conversion laboratories of APAAN into BMK in Europe 
during the 2009–11 period (Europol, 2011a). In Poland, three clandestine facilities manufacturing 
BMK from phenylacetic acid for sale to amphetamine manufacturers have been dismantled since 
the early 2000s (Krawczyk et al., 2009). Recently, the INCB has reported the dismantling of 
clandestine amphetamine production sites using phenylacetic acid in Germany and Spain in 2010 
(INCB, 2011).
Owing to concerns over an increase in global seizures since 2006, phenylacetic acid was 
rescheduled on 17 January 2011 from Table II to Table I of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988 (INCB, 2011). Phenylacetic acid 
is now placed under the same type of international control as the substance of which it is an 
immediate precursor, BMK, which is also in Table I.
Up until late 2004, the BMK used in European clandestine facilities was almost exclusively sourced 
from the People’s Republic of China and smuggled by Chinese organised criminal groups in large 
quantities into major EU ports including Antwerp, Hamburg and Rotterdam (Europol, 2007b). In 
2004, BMK seizures in China totalled 23 345 litres, while in 2003 and 2004, record seizures of 
6 109 litres and 9 297 litres of BMK, respectively, were made in Europe, largely in the 
Netherlands and Poland (INCB, 2007). A trend in BMK trafficking has been identified from 
mid-2004. Sourced from the Russian Federation, BMK has been smuggled via Latvia, Belarus, 
Lithuania, Finland, Estonia, Denmark, Poland and Germany, for use in large-scale amphetamine 
production sites in the Netherlands and, to a lesser extent, in Belgium and Poland (Europol, 2007a; 
Krawczyk et al., 2009). Forensic profiling information indicates that the vast majority of the BMK 
seized in the EU in 2005–09 had a stable and unique impurity or marker pattern, identified as the 
presence of 4-tert-butyl, the so-called ‘TB-factor’ (TB-BMK), which, at that time, was unique to BMK 
of Russian origin (Europol, 2007a).
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BMK seized in Europe: clockwise from top left, De Heen, Kerkrade and Yerseke, the 
Netherlands (all 2010) and Warsaw, Poland (2007). Source: Europol (2010b).
In theory, a range of different methods and chemicals may be used to illegally manufacture BMK. In 
practice, however, only a few are effectively applied by those operating clandestine laboratories 
(Europol, 2008). The following processes have been frequently used to obtain BMK:
•  synthesis of BMK from phenylacetic acid (in combination with acetic acid or acetic anhydride); 
•  synthesis of BMK from benzyl cyanide;
•  synthesis of BMK from benzaldehyde and nitroethane (so-called ‘nitropropene route’) (Krawczyk, 
2005); and
•  transformation of alpha-phenylacetoacetonitrile (2-phenylacetoacetonitrile) into BMK (Europol, 
2011a).
The first three production methods have been used in illicit laboratories in Poland in the past 
(Krawczyk et al., 2009), and the production of BMK from nitropropene was reported to Europol by 
Iceland (Europol, 2008). The last method was reported recently in Belgium, the Netherlands, 
Poland and Turkey (Europol, 2011a).
Despite self-production of BMK in Europe from ‘pre-precursors’, BMK continues to be smuggled into 
Europe, notably by organised crime groups from Russia and China. This is illustrated by recent 
seizures of 5 tonnes of BMK in Belgium (sourced from China) in August 2010, and 290 kg of BMK 
seized on the Lithuania–Poland border in July 2011.
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Masked — converted form of BMK 
In recent years, intelligence reports have indicated that criminal groups may have started to ‘mask’ 
BMK. This process involves the temporary conversion of the precursor into other ‘legal’ substances 
not placed under control. In 2008, a large-scale illicit synthetic drugs production site was 
dismantled by Dutch police. During the crime scene investigation, BMK was found in converted 
form — as a white powder rather than a yellow liquid. Subsequent forensic examination confirmed 
that the process of converting BMK powder into a liquid had taken place inside the production 
facility. The powder form of the BMK was identified and named by the Netherlands Forensic 
Institute (NFI) as BMK bisulphite adduct (Europol, 2009a) (3).
According to the NFI, a simple chemical process is used to transform the BMK and no specialised 
chemical knowledge is required. BMK bisulphite adduct is a white, moist, crystalloid, solid 
substance that looks like damp sea salt.
BMK bisulphite in powder form (the Netherlands, 2009). Source: Europol and KLPD, the Netherlands.
In May 2009, Europol received reports of the attempted trafficking of the BMK bisulphite adduct 
from the Russian Federation to the EU. A shipment totalling 2 600 kg of BMK bisulphite was seized 
during a customs clearance at the border checkpoint between the Russian Federation and Latvia. 
However, this phenomenon has not been reported in Europe since then.
(3)  An adduct is a product of direct addition of two or more distinct molecules, resulting in a single reaction product 
containing all atoms of all components, with the formation of two chemical bonds and a net reduction in bond 
multiplicity in at least one of the reactants.
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The European user markets for amphetamine
An estimated 2 million Europeans used amphetamines at least once during the last year, while 12.5 
million (3.8 % of European adults) have used them at some stage in their lives. As far as young 
European adults (15–34 years) are concerned, an estimated 6.5 million of them have tried 
amphetamines, equivalent to 5 % of that population, and 1.5 million (1.1 %) have used them 
during the last year. It is important to note that amphetamines consumption varies considerably 
between countries: the highest levels of use (15–34 years) are reported in Norway, Denmark, 
Latvia and the United Kingdom, and the lowest levels in Greece, Cyprus, Malta and Romania.
Amphetamine and methamphetamine are often sold as powders or tablets that look very much 
alike. Although methamphetamine is a more potent central nervous system stimulant, the effects of 
the two drugs are similar, and even experienced users may not be able to distinguish between the 
two, especially as the purity of street samples of both drugs may vary considerably. Of the two 
drugs, amphetamine is by far the most commonly available in Europe. In many countries, especially 
in the north, centre and east of Europe, amphetamines are the second most commonly used illicit 
substance after cannabis, and the most often used stimulant drug (see Figure 1). In countries such as 
Latvia, Finland and Sweden, use of amphetamine makes up an important part of the drug problem, 
and accounts for a substantial proportion of those seeking treatment. 
The patterns and geography of amphetamine use in Europe are harder to describe than for other 
widespread drugs. One reason for this is that the prevalence of amphetamine use varies 
considerably between countries. Second, it is difficult to establish a profile for the ‘typical’ 
amphetamine user. Amphetamine is used by a wide range of different populations including 
soldiers, lorry and taxi drivers, hospital workers, students, sex workers, clubbers and problem 
heroin users, in search of a diversity of effects including increased energy, alertness and 
concentration and decreased social or sexual inhibitions (EMCDDA, 2010a). In addition, European 
stimulant markets, especially in nightlife settings, are subject to shifts in the popularity of different 
drugs such as amphetamine, methamphetamine, cocaine, ecstasy and piperazines, and to the 
emergence of new substances such as mephedrone (EMCDDA, 2010b).
In terms of patterns of use, a recent study undertaken in six large European cities suggests that 
European amphetamine users, like users of most other widespread drugs, may be divided into two 
broad categories: integrated and marginalised consumers (Eisenbach-Strangl et al., 2009). Integrated 
consumers tend to be younger and better educated, and are more likely to have secure and stable 
accommodation or live with their parents. They also tend to enjoy a regular income from steady 
employment. More socially integrated users are also likely to be frequent consumers of cannabis. 
Typically, use among this group takes place in recreational settings and may be instrumental in the 
sense that it allows the user to stay up and out longer than would otherwise be the case. Findings 
from qualitative studies suggest that use of amphetamine has been a stable feature for years in certain 
music scenes (techno, rock, etc.) and in some rural areas. Amphetamine is usually sold at a low price, 
which makes it attractive to those who cannot afford more expensive stimulants such as cocaine. This 
may explain why the popularity of amphetamine is growing among young people living in small 
towns or in the countryside. On the other hand, amphetamine is sometimes viewed as a low-status 
drug used by ‘losers’ who cannot afford better-quality drugs (EMCDDA, 2010a). 
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Figure 1.  Dominant illicit stimulant drug in European countries (based on last 12 
months prevalence of amphetamines and cocaine use among young adults 
(aged 15–34) measured by latest available national population surveys)
Amphetamines prevail
Cocaine prevails
Neither prevails
No data
Source: EMCDDA Statistical bulletin 2011.
Although the majority of amphetamine users across Europe are socially integrated recreational 
users, there a smaller number of more marginalised or problematic users of amphetamines, many of 
whom administer the drug by injection. Studies suggest that these users are often characterised by 
low education status, homelessness, lack of regular employment and frequent contact with the 
police. Many of them report incomes from illegitimate sources such as drug dealing and petty theft 
or from prostitution and begging. This group is likely to have more contact with health and social 
services and may benefit from interventions that target their social marginalisation as well as their 
drug problems. Injection rates are very high among this marginalised population, and sometimes 
involve both opiates and amphetamines. Injecting amphetamines carries the same risks of viral 
infection as injection of other drugs, including an increased risk of HIV, hepatitis C infection, etc. 
(Eisenbach-Strangl et al., 2009), although, generally, studies of amphetamine injectors in Europe 
have tended to report lower rates of HIV infection than typically found among opiate injectors. 
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Recent EMCDDA data on problematic amphetamines use in Europe suggest that in 2009 a total of 
approximately 20 000 people in 28 European countries entering drug treatment reported one of 
the amphetamines as their primary drug, around 40 % of whom were entering drug treatment for 
the first time. Compared with other drugs such as heroin and cocaine, this is a relatively small 
number. Additionally, around 20 000 treatment entrants reported amphetamines as their secondary 
drug, frequently in combination with opioids. Problematic amphetamines use is a differentiated 
phenomenon that takes different forms in different regions. In Europe, three geographical areas 
may be distinguished: northern Europe, western and southern Europe, and eastern and central 
Europe (EMCDDA, 2010a).
Concerns associated with use of amphetamines are more apparent in the north of Europe than in 
the rest of the continent. In Sweden and Finland, problematic amphetamines use is at the heart of 
the drug problem, and in neighbouring Denmark and Norway it is also a significant issue, with 
levels of use in the general population above the European average. A notable trend in northern 
Europe since the early 2000s is the increasing availability of methamphetamine on some national 
markets, especially Norway and Sweden, and a concomitant decrease in amphetamine. In fact, 
convergent supply-side and demand-side data series seem to suggest that in these two countries 
methamphetamine is displacing amphetamine in the illicit market, at least for the time being. 
In several countries of central and eastern Europe, use of amphetamines is a significant problem. 
The cases of the Czech Republic and Slovakia, where the most widespread of the amphetamines is 
methamphetamine, have been described elsewhere (EMCDDA, 2009b, 2010a). In other countries 
in the region — Estonia, Hungary, Latvia, Lithuania and Poland — both amphetamine and 
methamphetamine seem to be present, albeit in different proportions. Primary use of amphetamines 
is reported by between 2 % (Estonia) and 44 % (Hungary and Latvia) of those entering treatment 
and declaring opioids, cocaine or amphetamines as their primary drug. Polydrug use seems to be 
common among amphetamine users in the region, especially involving opioids. 
In western and southern Europe, amphetamines users account for a small proportion of problem 
drug users, and there are typically twice as many men as women in this group. In the majority of 
countries in this region, primary amphetamines users account for less than 5 % of those entering 
treatment for opioids, cocaine or amphetamines problems. The proportion is higher, however, in 
three countries: Belgium (17 %), Germany (12 %) and the Netherlands (10 %). 
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Trends in amphetamine production 
and trafficking in Europe
Patterns and trends in amphetamine seizures
Amphetamine produced in the EU is trafficked extensively within Europe, and some is exported 
abroad but in quantities that remain difficult to determine. In 2009, an estimated minimum of 
34 200 seizures, amounting to 8.7 tonnes of amphetamine, were made in Europe. Out of this total, 
8.0 tonnes was seized in the form of powder and the rest was made up of 3 million amphetamine 
tablets (4).
Challenges in the analysis of amphetamine seizures
The EMCDDA collects, on a routine basis, annual data on the seizures of illicit drugs — both numbers of seizures 
made and quantities intercepted — by country, in the EU Member States, Croatia, Turkey and Norway, via its 
Reitox network of national focal points. This data set is validated by the reporting countries and published online. 
A second source of data on drug seizures is Europol, which, in support of its on-going activities in the fight 
against production and trafficking of illicit drugs in Europe, collects data on quantities of drug seized annually in 
the EU Member States. This data set is somewhat less detailed and not published. The third source of information 
on drug seizures is the UNODC, which publishes worldwide annual data on the quantities of illicit drugs seized 
by country, based on national responses to the Annual Report Questionnaire (ARQ). 
The number of amphetamine seizures made in Europe is therefore available only from the EMCDDA. The main 
problem in this data set is that two countries — the Netherlands and Poland, which are major producing and 
seizing countries — do not report on the number of amphetamine seizures made on their territory.
Data on the quantities of amphetamine seized in Europe may be sourced from the three institutions mentioned 
above. The main issue here is that the three data sets can at times be highly inconsistent for some countries, 
with figures presenting large variations depending on the source. For instance, in one case millions of tablets 
were reported to one of the sources but not to the other two. Whereas, in some cases, the differences are 
negligible, or the data could be reconciled because at least two of the sources reported identical or close data 
sets, in other instances it was very difficult to decide which of the three alternatives reflected the reality or 
could be viewed as the best approximation to it. Several factors may explain such differences, including 
differences in data collection instruments and methods, data providers, timeframe for data collection, potential 
updates, checking practices and validation processes.
In addition, amphetamine products can take various forms, including powder, tablet and, more rarely, liquid 
and paste. These different forms may raise additional issues in terms of data reporting and analysis. 
In order to ensure consistency between data sets, in particular between the number of seizures and the 
amounts recovered, the data analysed in this section were sourced primarily from the EMCDDA and, where 
missing, completed with Europol data. In the case of individual country analysis in Figure 4, and where there 
were inconsistencies between EMCDDA and Europol data sets, both estimates obtained are provided.
(4)  The analysis of seizures presented in this section covers the 30 EMCDDA reporting countries, which are designated 
by the term ‘Europe’ in the text and include the 27 EU Member States, Croatia, Turkey and Norway.
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Figure 2 shows the total number of annual seizures (where reported) and quantities intercepted in 
Europe since 2005. The total amounts represent the sum of the quantities of amphetamine seized 
under different forms, including powder, tablets, liquids and paste.
Figure 2.  Seizures of amphetamine in the EU, Norway, Turkey and Croatia, 2005–09
0
2
4
6
8
10
12
2005 2006 2007 2008 2009
Tonnes
0
10
20
30
40
50
Number (000s)
Quantity seized Number of seizures
Notes:
Number of seizures: (a) In the absence of 2009 data, 2008 data were used to construct the 2008 European total. (b) 
Data on the number of seizures are not reported by the Netherlands and Poland, and therefore are not included in the 
European totals.
Quantities seized: (a) In the absence of 2008 and 2009 data from some countries, data reported to Europol were used 
to construct European totals. (b) The total quantity seized each year includes the number of tablets reported, assuming for 
conversion purposes an average weight of 250 mg per tablet, and the number of litres of liquid amphetamine reported, 
assuming that 1 litre weighs 1 kg. Seized amphetamine powders and tablets rarely contain pure amphetamine; they are 
usually a mixture of amphetamine and other substances (adulterants). If adjusted for purity, seized quantities of powders 
and tablets would probably be substantially lower.
Data used in this graph include seizures made in Croatia, Turkey and Norway.
Preliminary data for 2010 reported to Europol indicate a total of 2 643 kg.
Source: EMCDDA (Reitox national focal points).
The number of amphetamine seizures in Europe has been fluctuating for the last 5 years, with a 
decrease reported in 2008 and 2009 (see Figure 2). However, this analysis is limited by the fact 
that major seizing countries do not report the number of seizures made (see ‘Challenges in the 
analysis of amphetamine seizures’ box, p. 22).
Quantities of amphetamine powder recovered in Europe have stabilised at a high level: between 7 
and 8 tonnes has been recovered annually in Europe since 2004, with a low of 5.5 tonnes in 
2006 and a peak of 8.2 tonnes in 2007. The largest amounts of amphetamine powder were 
recovered in the United Kingdom, where the cumulative quantity seized between 2005 and 2009 
has been estimated to be nearly 10 tonnes (including several individual seizures between 100 and 
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500 kg), followed closely by the Netherlands with nearly 9 tonnes, and then Germany with just 
under 5 tonnes, Bulgaria with 3 tonnes, and Poland and Sweden, each of which seized close to 2 
tonnes (see Figure 4). 
Of the 3 million amphetamine tablets seized in Europe in 2009, almost all was accounted for by 
Turkey with the interception of a total of 2.8 million captagon tablets. Turkey has long been the 
principal country for seizing amphetamine tablets in Europe, with several millions of captagon 
tablets intercepted every year since 2002, and a record of 20 million in 2006. It should be noted 
that seizures of captagon tablets represent production that is mostly not intended for consumption in 
the EU, and this fact needs to be taken into account when interpreting overall trends in cumulative 
seizures, which include drugs intended for both EU and non-EU consumption. The amounts 
recovered in Turkey in 2008 and 2009 have remained at just under 3 million and seem rather low 
compared with previous years, perhaps pointing to a displacement of the manufacture of captagon 
tablets outside south-east Europe. Altogether, Turkey intercepted a cumulative total of 40 million 
captagon tablets (equivalent to 10 tonnes of captagon tablets) (5) over the period 2005–09, which 
makes it the country seizing the largest quantities of illicit amphetamine products in Europe (6) (see 
Figure 4), although clearly not the country seizing most amphetamine intended for consumption in 
Europe. This could be explained by the geographical position of Turkey on the route to the 
captagon consumer countries in the Middle East. 
Other European countries, although much further behind Turkey in terms of quantities intercepted, 
regularly report seizing tens of thousands of amphetamine tablets every year. This is the case of 
Spain, for example, which seized nearly 100 000 tablets in 2009 and a record of more than 
340 000 in 2006. Significant quantities of seizures have also recently been reported by Hungary 
(80 000 tablets seized in 2009) and Portugal (130 000 in 2008). 
Amphetamine production and trafficking in Europe
Europol has monitored seizures of facilities involved in the illicit production, tableting and storage 
of synthetic drugs, and related waste dump sites, in the EU since 1999. Figure 3 provides an 
overview of the amphetamine production, tableting and storage sites detected in the EU and 
reported to Europol between 2007 and 2010. It suggests that most of the amphetamine production 
facilities detected in recent years were located in northern Europe (north-west and north-east 
criminal hubs, see ‘EU criminal hubs’ box). UNODC data confirm that this has been the case at 
least since the early 1990s (UNODC, 2003). However, some facilities have also been dismantled 
in the south-east of Europe, in Balkan and Black Sea countries, probably in connection with the 
extra-European trade in captagon (see below). 
(5)  For this calculation, an average weight of 250 mg per tablet was used.
(6)  This comparison is based on the gross weight of the illicit amphetamine products seized (mainly powders and 
tablets). Note that this weight is not adjusted for purity. Illicit amphetamine products rarely contain pure 
amphetamine. They usually contain several other substances in a proportion that varies widely across samples and 
countries, but may be relatively large (over 99 % in some cases).
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Figure 3.  Dismantled amphetamine production, storage and tableting sites, 
as reported to Europol, 2007–10
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Closer examination of the Europol information combined with EMCDDA seizure data (see Figure 4) 
and other sources further suggests that amphetamine production and trafficking in Europe can be 
thought of as concentrated in geographically distinct areas. The two most important of these broadly 
correspond to the north-west criminal hub (centred on the Netherlands and Belgium, but for 
amphetamine Denmark and the United Kingdom are also important) and the north-east criminal hub 
(although with the caveat that for amphetamine Poland is also strategically important in this latter 
geographical area). In addition, significant production, albeit at lower levels, is also found in Germany 
and some other central European countries. Lastly, and somewhat distinctly for reasons already noted, 
Bulgaria and Turkey are also important sources of captagon production for export outside Europe. 
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Figure 4 shows cumulative data for amphetamine seizures over the period 2005–09 in the 10 
countries in Europe seizing the largest quantities of amphetamine (all forms included). We have 
calculated, based on the 5-year cumulative data from Figure 4, the average seizure size in each 
country over the 5-year period by dividing the total quantities seized by the total number of seizures 
in each country. Seizure data primarily reflect law enforcement activities (organisation, priorities, 
resources), but they are also an indirect reflection of different patterns of amphetamine 
trafficking (7). Both Turkey, which accounts for the largest quantities over the period but, at the same 
time, the lowest number of seizures, and Bulgaria, which ranks fifth in terms of quantities recovered, 
are characterised by average seizures in the order of kilograms — 39 kg and 8 kg, respectively. 
This points to a high prevalence of wholesale trafficking in amphetamine in these two countries, 
and is probably a reflection of the fact that south-east Europe has been identified as an area of 
amphetamine production, especially of captagon. 
Figure 4.  Largest quantities of illicit amphetamine products seized in the EU, 
Norway and Turkey, cumulative total for 2005–09 (tonnes)
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Notes:
The figure represents the total quantities of illicit amphetamine products seized cumulated over 2005–09 for each of the 
top 10 seizing countries in Europe. Quantities reported in weight, in number of tablets and in litres are included in the 
totals. For conversion purposes, amphetamine tablets were assumed to weigh on average 250 mg each, and 
amphetamine liquids to weigh 1 kg per litre. The number between brackets is the estimated number of seizures (reported 
to the EMCDDA) for 2005–09; unavailable data were approximated by adjacent data points.
The ranking of countries is based on the gross weight of the illicit amphetamine products seized (mainly powders and tablets), 
without adjustment for purity. Available data show that illicit amphetamine products contain between 0.1 % and 75 % of 
amphetamine sulphate in the EU, Norway, Croatia and Turkey. As a result, if quantities seized were adjusted for purity, amounts 
of illicit amphetamine products seized would be much lower, and it is possible that the ranking of the countries would be different.
Data from the EMCDDA and Europol were used. Where there were inconsistencies between data sets, both the lowest and 
highest figures are reported, with a change in colour representing the lower estimate and the top of the bar the highest one.
Data from Germany for 2005 include both amphetamine and methamphetamine seizures.
Sources: EMCDDA (Reitox national focal points) and Europol.
(7)  A limitation of this method is that it does not provide information on the real distribution of the size of seizures in a 
country.
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France, where amphetamine production has not been detected and where prevalence of use is low, 
appears to be a transit country for amphetamine destined to larger consumer markets such as Spain 
and the United Kingdom, with an average seizure size of around 0.5 kg. The low average seizure 
size in the United Kingdom (200 g) is likely to result from a mixture of street-level deals in a country 
where amphetamine use is widespread and mid-level to wholesale trafficking for supplying such a 
market. In Belgium, where amphetamine manufacture also occurs, the average seizure is 100 g. 
The relatively high average size of amphetamine seizures (140 g) in Germany probably reflects the 
extent of the amphetamine consumer market in Germany, which is characterised by medium to high 
levels of use in young adults, as well as the fact that Germany is an amphetamine producer as well 
as an importer country, and a transit country for amphetamine produced in Poland and other 
countries on the Baltic Sea making their way south and north (see below). 
Finally, data from both Sweden and Norway reveal average seizures of around 60 g, which, as 
for the United Kingdom, might be indicative of a large consumer market for amphetamine and of 
the distribution networks that such markets entail at all levels of the supply chain. However, 
although a large proportion of amphetamine use in the Nordic countries is problematic, which 
possibly entails larger quantities consumed per user compared with the United Kingdom, where 
most users are recreational, the total market is much smaller in these countries than in the United 
Kingdom because of their smaller populations. Amphetamine data from the Nordic countries are 
also likely to reflect the fact that methamphetamine consumption and trafficking seem to have 
increased greatly in these countries in recent years, with methamphetamine gradually replacing 
amphetamine as the most frequently used stimulant (EMCDDA, 2009b).
Data on the number of seizures are not available for the Netherlands and Poland, but the relatively 
large quantities seized in both countries, especially in the Netherlands, seem to confirm that 
significant amphetamine manufacturing occurs in both countries.
28
Issu
e No
 3: A
mphe
tamine
EU criminal hubs (1)
1
2
3
4
5
1. North-west criminal hub — centre of gravity, the Netherlands and Belgium.
2. North-east criminal hub — centre of gravity, Lithuania, Estonia, Latvia, Kaliningrad exclave (Russia).
3. South-east criminal hub — centre of gravity, Bulgaria, Romania and Greece.
4. Southern criminal hub — centre of gravity, southern Italy.
5. South-west criminal hub — centre of gravity, Spain and Portugal.
(1)  Note that centres of gravity as identified by circles on the map are approximate and do not designate cities or regions of 
prolific criminal activity.
The ‘north-west hub’
The north-west hub, centred on the Netherlands and, to a lesser extent, Belgium, is the largest area 
of manufacture of amphetamine in Europe, and it is likely to be the largest source of the 
amphetamine consumed within Europe. It is the region where the largest quantities of amphetamine 
are confiscated, and is among the largest for number of seizures. The north-west hub may also be 
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the region of Europe where the largest quantities of amphetamine are consumed; at the very least, 
it contains what is probably Europe’s largest consumer market for the drug, the United Kingdom 
(Europol, 2007b; UNODC, 2008b).
It should be noted that information on amphetamine production and trafficking (as well as use) in 
the north-west hub is comparatively more abundant and more detailed than in other areas, which 
may reflect the priorities and resources of the law enforcement agencies in this area. 
Europol reports that amphetamine synthesis and tableting facilities in the north-west hub are 
concentrated in the Netherlands and, to a lesser extent, in Belgium. Occasional dismantling of 
facilities in recent years suggest that some limited amounts may also be produced in the United 
Kingdom (see Figure 3), where significant amphetamine production has occurred in the past 
(UNODC, 2008b). In addition, an amphetamine laboratory was dismantled in Luxembourg in 
2003. Most of the large amphetamine production sites seized in the region featured sophisticated 
reaction vessels, tableting machines, heating mantels and other equipment, such as punches with 
logos. This equipment is either custom-made or diverted, new or second-hand, from the licit market 
for industrial equipment in Europe and elsewhere. The facilities and equipment used to manufacture 
amphetamine in Belgium and the Netherlands are also often used to produce MDMA, the active 
ingredient in ecstasy. Since the early to mid-2000s, the capacity of both the reaction vessels and 
the tableting machines seized from Belgian and Dutch production sites has increased to reach 
large-scale capacity, i.e. the ability to produce between 20 and 50 kg of amphetamine a day. 
High production capacity seems to be a characteristic feature of the north-west hub as the facilities 
dismantled elsewhere in Europe have so far tended to be smaller. However, as detailed information 
on facilities manufacturing captagon is not available, this remains a tentative conclusion.
There have been some seizures of amphetamine precursor chemicals in the north-west hub in recent 
years, but they are unlikely to reflect the full scope of amphetamine production there. In 2009, for 
instance, total seizures of amphetamine precursors in the north-west hub comprised just 207 litres of 
BMK and 165 kg of norephedrine in the Netherlands, and 120 litres of BMK in Belgium. However, 
it is probable that a significant proportion of the BMK seized in central Europe and the north-east 
hub was in fact destined for the north-west hub. 
The Dutch Reitox national focal point quoted in 2009 a research report suggesting that Dutch 
production experts cooperate with illicit amphetamine manufacturing groups in Belgium, Poland 
and the Baltic States. Europol reports that Dutch, British and Belgian criminal groups appear to 
dominate large-scale amphetamine trafficking. British traffickers, sometimes residing in the 
Netherlands or Spain, seem to control movements of large consignments to the United Kingdom. 
Several seizures in the United Kingdom have been part of multi-commodity consignments, including 
also substantial quantities of cannabis, cocaine and heroin. A relatively recent trend is for 
amphetamine to be exported in a wet or paste-like state to the United Kingdom, where it is re-
packed for subsequent distribution. 
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Dutch amphetamine production
The production of amphetamine is widespread in the Netherlands, as illustrated by the seizure in the first half of 
2011 of some 365 kg of amphetamine and 10 litres of amphetamine oil that were linked to production sites in 
the Netherlands. In addition, during this period two BMK conversion labs were dismantled while 10 
amphetamine-related waste dump sites were identified. In 2010–11, several mid- to large-scale amphetamine 
production laboratories were discovered in the Netherlands. Production is mostly located in the southern part of 
the Netherlands, in the border area with Belgium and Germany. Most production sites are in rural and/or 
commercial sparsely populated areas. The cross-border nature of production in this area is illustrated by the recent 
discovery of a partly dismantled amphetamine laboratory in Belgium, where 60 kg of amphetamine and BMK 
was seized. Criminal investigations suggested that the Belgian laboratory was associated with a Dutch criminal 
group. Amphetamine production in the Netherlands can be regarded as relatively sophisticated compared with 
that in other parts of Europe. This can be seen in efforts made to conceal large production sites, which can include 
noise reduction measures and the use of carbon filters to avoid odours. Custom-made equipment is also often 
used, including stainless steel vessels of high capacity. Most amphetamine is produced in the Netherlands by the 
Leuckart method, which requires the use of BMK. The United Kingdom is probably the largest export destination 
for Dutch amphetamine, followed by the Scandinavian countries (Smits, 2007; Vijlbrief, 2011).
Some amphetamine production is also reported, albeit on a smaller scale, in Germany, especially 
southern Germany. A total of eight illicit amphetamine production facilities were seized in 2009 
and 2010 (BKA, 2009a, 2010). One of the reasons for this fairly limited amphetamine production 
is likely to be the success of supply reduction activities resulting from cooperation between the 
chemical industry and law enforcement agencies (UNODC, 2008b). Another likely reason is that 
the majority of the German consumer market for amphetamine is supplied with drugs manufactured 
elsewhere, in particular Poland and, to an even greater extent, the Netherlands. 
Illicit amphetamines production in Germany is a fairly long-standing phenomenon, dating back to 
the 1970s at least, and seems to be especially prevalent in Bavaria, often in the north of the Land 
bordering the Czech Republic, where around 45 clandestine amphetamines laboratories were 
dismantled between 2001 and 2010 (BLKA, 2011). Amphetamine production also seems to occur 
with some frequency along an axis stretching from Germany’s southern borders with Switzerland 
and Austria (Bade-Württemberg and Bavaria Länder) up to Dortmund in the north, via the Stuttgart, 
Frankfurt and Cologne areas. Most of the amphetamine (and methamphetamine) facilities 
dismantled in Germany seem to be small in scale, mostly ‘kitchen-type’ labs. It is also worth noting 
that significant quantities of BMK, a key precursor for amphetamine that may also be used to 
produce methamphetamine, have been seized in Germany in recent years, including 100 litres in 
2009 (BKA, 2009b), 243 litres in 2007 and 1 310 litres in 2005. In addition, 26 kg of 
phenylacetic acid, a precursor of BMK, were seized in the country in 2009 (INCB, 2011). It is 
likely that most of the precursors confiscated in Germany were in transit from the north-east hub (see 
below) to the north-west hub, although some limited quantities were probably intended for illicit 
amphetamines manufacture in Germany or in other countries of central Europe.
While there is little doubt that most of the amphetamine manufactured in Germany is consumed 
locally, some may be exported abroad. In addition, Germany is probably a transit territory for 
amphetamine produced in the Netherlands and in the north-east hub (see below), especially Poland 
and Lithuania, and smuggled to Nordic countries including Sweden (Nilsson and Kegö, 2009). 
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To summarise, it would seem that Germany is primarily a zone of transition, where small amounts 
of amphetamine are produced, but fairly large quantities are consumed and therefore imported, 
and which is crossed by flows of precursor chemicals travelling west from the north-east hub to the 
north-west hub and flows of amphetamine sulphate travelling north to Scandinavia. 
National reports of the Reitox focal points for 2009 and 2010, Europol information and the 
UNODC (2008b) converge to indicate that the north-west hub is the main source of the 
amphetamine consumed in most western European countries including the United Kingdom, 
Germany (see below), Spain, the Netherlands and Belgium (8), countries which have large to 
middling consumer markets for amphetamine. Some amphetamine from the north-west hub is also 
exported to northern European markets, including Norway, Sweden and Denmark, and is reported 
to be found in central and southern European markets such as in Austria, Hungary, Croatia, Greece 
and Italy. 
The ‘north-east hub’
Significant production and trafficking of amphetamines occurs in the north-east hub, especially in 
Poland and, apparently to a lesser extent, in Lithuania and Estonia. In Latvia, very limited illicit 
production was identified and suppressed in the late 1990s, although intelligence obtained in 
2010 indicates a possible renewal of amphetamine production in the country. Likewise, sporadic, 
limited production has been detected in the past in Finland and Sweden (UNODC, 2008b). 
Judging from seizure data and intelligence and forensic reports, it would appear that the quantities 
produced in the north-east hub are smaller than in the north-west hub, but larger than in central 
Europe. 
Poland, which seems to be the north-east hub country where the largest quantities of amphetamine 
are manufactured, is often viewed as the second or third largest amphetamine producer in northern 
Europe, after the Netherlands and just before or just after Belgium depending on the source 
(UNODC, 2008b; Krawczyk et al., 2009). Some 95 % of the 160 illicit production facilities 
dismantled in Poland since 1995 produced amphetamine sulphate (Krawczyk et al., 2009). 
(8)  Several large seizures of amphetamine were made in France in recent years, but Europol information indicates that 
most of these large shipments were in fact intended for the UK market and, to a lesser extent, the Spanish market.
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Amphetamine sulphate (11 kg) drying under hot lamps — clandestine production facility seized at Jażwie, Poland (2001). 
Source: Central Bureau of Investigation, National Police Headquarters, Warsaw, Poland.
The general pattern for some years in the north-east hub has been that amphetamine, and 
increasingly methamphetamine (EMCDDA, 2009a), is produced for local consumption, which is 
increasing, and for export to Scandinavian countries, especially Sweden, Finland and Norway, 
and, perhaps to a lesser extent, Denmark. In addition, smaller amounts are likely to be exported 
from Poland to neighbouring Germany and Hungary, and further away, for example to Croatia. 
Closer examination of the information available suggests that there may be trafficking networks 
linking specific producer countries to specific consumer countries. For instance, several reports 
suggest that amphetamine produced in Lithuania and, to an even greater extent, Poland is exported 
mostly to Sweden (UNODC, 2008b; Nilsson and Kegö, 2009; Pullat, 2009), whereas the primary 
consumer market for the amphetamine manufactured in Estonia would appear to be to be Finland 
(Pullat, 2009; THL, 2009). In Poland (Krawczyk et al., 2009), Estonia (Pullat, 2009) and Lithuania 
(Gutauskas, 2009), most amphetamine production appears to be in the hands of organised gangs 
of traffickers. 
Polish, Estonian and Lithuanian criminal organisations also seem to be involved in amphetamine 
export to and trafficking within the Scandinavian countries, mostly in partnerships with local 
traffickers (Käll, 1997; Svensson, 2009). An original method is reported to be often used to traffic 
amphetamines between Estonia and Finland: Estonian traffickers first bury a quantity of drugs in a 
secret location in Finland and then sell a map, or global positioning system (GPS) coordinates, to 
Finnish buyers, who then distribute the drugs in Finland (Pullat, 2009; THL, 2009). Moreover, 
intelligence reported to Europol suggests the growing prominence of Polish and Lithuanian criminal 
groups in trafficking drugs obtained in the Netherlands to various Nordic and Baltic States, Ireland 
and the United Kingdom, as well as the United States and the Russian Federation. It is also possible 
that some criminal organisations of the north-east hub are involved in trafficking amphetamine (and 
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other synthetic stimulants) made in the Russian Federation, where a large number of facilities 
manufacturing synthetic drugs have been dismantled in recent years, especially in the Saint 
Petersburg region (UNODC, 2008b), which is close to Estonia. Europol reports that north-east hub 
organised crime groups closely cooperate with their counterparts in the north-west hub. For 
example, a north-east hub group may receive half of the amphetamine produced by a north-west 
hub group in return for trafficking BMK to the north-west hub (Europol, 2011b).
It should be noted that in Estonia, and to a greater extent Lithuania, the production of 
methamphetamine is now higher than that of amphetamine (EMCDDA, 2009a). This appears not to 
be the case in Poland, where in recent years very few facilities making methamphetamine have 
been dismantled, and the production capacity of amphetamine facilities is reported to have 
increased (UNODC, 2008b; Krawczyk et al., 2009).
In Poland, Lithuania and Estonia, the precursor chemical used to produce amphetamine (and 
methamphetamine) seems to be almost exclusively BMK imported from the Russian Federation 
(Europol, 2007b; Estonian Focal Point, 2009; Krawczyk et al., 2009). Quantities of BMK ranging 
from a few litres to a few hundred litres are seized every year in Poland, Lithuania and Estonia. The 
aggregate quantity of BMK seized in all three countries and reported to the INCB over the period 
2005–09 totals 2 421 litres, approximately 60 % of which was seized in Poland (1 484 litres) 
(INCB, 2011). These relatively large quantities reflect the importance of the north-east hub as both 
an amphetamine producer region and a transit zone for BMK sourced in Russia and destined 
primarily for the north-west hub (Europol, 2007b; UNODC, 2008b; Estonian Focal Point, 2009; 
Krawczyk et al., 2009). 
Polish amphetamine production sites
Illegal amphetamine manufacturing facilities dismantled in Poland are typically located in a small town or a 
village, in isolated detached houses, although some facilities have been detected in apartment buildings. 
Although amphetamine manufacturing does not require large amounts of power or water (a Polish clandestine 
laboratory’s electricity and water consumption is reported to be similar to that of an average household), the 
facility must have access to electricity and water. The water may come from the municipal system, a well or a 
closed-circuit system based on tanks. The electricity is frequently diverted illegally from the mains supplies.
Production facilities are reported to be often set up by organised criminal gangs, which employ chemists and 
operators. The chemists, who usually have a degree in chemistry, design the entire manufacturing process. 
They specify the chemicals and equipment needed, the proportions of precursors (usually BMK) and reagents 
to be used, and the time and temperature required for each step (e.g. distillation, extraction, drying, 
grinding). These amphetamine ‘recipes’ are usually written in simple terms, so that they may be understood by 
lay persons, as the chemists are rarely personally involved in the production process at the site. This is left to 
the operators, who are usually not familiar with chemistry and may not know the exact nature of the substance 
they are producing. Operators are trained to strictly follow the instructions prepared by the chemists and to 
operate the equipment. Operators are the most vulnerable actors in the amphetamine production process 
because of their exposure to potentially dangerous controlled chemicals and drugs, and because they are in 
the front line, i.e. more likely to be arrested and then convicted (Krawczyk et al., 2009) (1).
(1)  Pullat (2009) gives a similar description of clandestine amphetamine production arrangements in Lithuania.
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Production and trafficking in central Europe
Production and trafficking of synthetic stimulants also takes place in central Europe, albeit on a 
smaller scale. Judging from data on seizures of clandestine facilities, production in central Europe is 
centred on Germany, although some facilities are occasionally found elsewhere in the region, for 
instance in Hungary in 2009 (see Figure 3). Although neither Hungary nor Austria ranks among 
Europe’s 10 largest amphetamine-seizing countries (see Figure 4), relatively high cumulative totals 
of amphetamine — 200 kg and 112 163 tablets in Hungary and 141.5 kg in Austria — seized in 
the 2005–09 period suggest that both countries are fairly significant players in central Europe. 
Slovenia is also thought to produce principally amphetamine, although amounts seized are much 
smaller, totalling only 10.2 kg and 2 291 tablets over the period 2005–09. Both Interpol and the 
INCB have reported dismantling of amphetamine production facilities in Slovenia in recent years. In 
contrast, in the Czech Republic and Slovakia, methamphetamine overwhelmingly dominates the 
production, trafficking and use scenes and amphetamine is practically absent (EMCDDA, 2009b).
Production and trafficking of captagon in the ‘south-east hub’ 
Captagon was originally the registered trademark of a medicinal product. Today, tablets sold as 
captagon account for a significant amount of seized illicit synthetic stimulants in several countries, 
particularly in the Near and Middle East. The drug has experienced a number of transitions since it 
was first developed for paediatric and geriatric use and given its trade name in the 1960s (UNODC, 
2009). The original captagon product contained phenethylline, which is metabolised in the human 
body to amphetamine. Today, the limited forensic data available show that seized captagon tablets 
do not contain any phenethylline, but mainly amphetamine sulphate (in a quantity of between 1 % 
and 16 % of the gross weight) and caffeine (in quantities between 5 % and 61 %), and usually an 
additional additive in combination with paracetamol and theophylline (Interpol, 2009). 
According to the UNODC (2009), trafficking in captagon in the Near and Middle East, especially the 
Arabian Peninsula, dominates global amphetamine seizures, with 23.6 tonnes (29 % of global 
seizures) being seized in this region in 2007. Captagon is popular among the younger, affluent 
population and has enjoyed a reputation as a sexual stimulant since the beginning of the 1980s 
(UNODC, 2009). Bulgaria and, to a lesser extent, Turkey, are believed to be the sources of captagon, 
with several indications that undetected amphetamine manufacture may also be occurring close to the 
consumer markets in the Near and Middle East. Moreover, over the past few years, Interpol and the 
INCB have reported seizures of clandestine laboratories in several south-eastern European countries, 
including Serbia, where 1 900 kg of phenylacetic acid was also seized in 2009 (INCB, 2011). 
Bulgaria reported to the UNODC the seizure of 18, frequently large-scale, amphetamine production 
facilities between 2001 and 2007 associated with the manufacture of captagon tablets (UNODC, 
2008b). The Bulgarian Reitox focal point network reported in 2008 that some amphetamine 
production had been moved out of Bulgaria, but that exports to Turkey, Lebanon, Georgia, 
Armenia and Syria had still been detected (Bulgaria NFP, 2008). Two years later, in 2010, 
Bulgaria reported the continuing production of amphetamine with one and three production sites 
seized in 2008 and 2009, respectively (Bulgaria NFP, 2010). 
According to the Turkish focal point of the Reitox network, Turkey is primarily a transit country for 
captagon manufactured in eastern European countries and in Syria and bound for the Middle East 
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and the Arabian Peninsula by road and by sea (TMCDD, 2009). However, tableting facilities have 
been detected in Turkey in recent years. For instance, in 2006, 12 illicit captagon production sites 
were dismantled in Turkey (UNODC, 2008b); in February 2009, 2.1 million tablets were seized at 
a clandestine facility where amphetamine was transformed into captagon tablets; and in September 
2009, 473 kg of amphetamine was seized at a captagon manufacturing site (KCM, 2009). 
Little information is available on how illicit amphetamine production is organised and what 
precursor chemicals are used to manufacture captagon. The production capacity of amphetamines 
facilities in Bulgaria was reported to be between 1.5 and 70 kg per month in 2001 (UNODC, 
2003). The very limited quantities of BMK and of its precursor, phenylacetic acid, that have been 
seized in Bulgaria and Turkey since the early 2000s are unlikely to reflect the scope of production 
there. In the 10-year period 2000–09, Bulgaria reported seizing an aggregate total of 373 litres of 
BMK and 528 kg of phenylacetic acid, while Turkey confiscated 225 litres of BMK and no 
phenylacetic acid (INCB, 2003, 2007, 2011). 
The Lebanese authorities intercepted laboratory equipment and precursor chemicals for captagon 
manufacture in 2007 (UNODC, 2009), and a large captagon laboratory was reported to be 
seized in Saudi Arabia in June 2010 (UNODC, 2010). Syria has been described as a transit 
country for captagon from Turkey and Lebanon to the Gulf States by US authorities (US INL, 2009). 
The Syrian authorities seized 6.8 million captagon tablets during the first 8 months of 2008. Saudi 
Arabia seized a record 13.9 tonnes of fake captagon in 2007. According to the UNODC, many 
of the drugs seized were destined to travel from Syria by road, via Jordan, to Saudi Arabia. 
Several countries in the subregion, including Jordan, Syria, the United Arab Emirates and Yemen, 
have reported dramatic increases in seizures of these tablets since 2004, typically via overland 
routes and often destined for Saudi Arabia’s large domestic market. A smuggling route by which 
captagon was transported to Iraq through Syria was recently detected.
Recent developments concerning precursor chemicals could confirm that large amounts of captagon 
are now manufactured in the Near and Middle East, including Iraq. The INCB reports that a shipment 
of 8 865 litres of the amphetamine precursor BMK was made to Jordan in 2010. This was the largest 
single shipment made anywhere in the world in 2010, accounting for more than 50 % of the total 
quantity of BMK shipped internationally that year (14 690 litres) (INCB, 2011). In 2009, Jordan also 
accounted for most of the BMK shipped internationally. In addition, in 2009, authorities in India 
stopped shipments of 9 800 litres bound for Jordan and 3 900 litres destined for neighbouring Syria. 
The Jordanian authorities claimed that the BMK was intended to be used as a cleaning and 
disinfection agent, and reported that Iraq was the final destination of the shipment. However, because 
laboratory analysis of the cleaning product showed no trace of BMK, the INCB has expressed 
concern that recent BMK shipments to Iraq via Jordan may be illegitimate (INCB, 2011). 
It is likely that until recently captagon manufacturing in south-eastern Europe was the principal 
source of the captagon tablets consumed on Near and Middle East markets. This may no longer be 
the case following the probable displacement of at least some captagon production in the Near 
and Middle East region in recent years. The information available at this stage makes it difficult to 
draw any definite conclusions in this respect. However, until recently it is likely that south-eastern 
Europe was the region of Europe where either the largest or the second largest quantities of 
amphetamine were illicitly manufactured, just before or just after the north-west hub.
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European and international initiatives
The EU, its Member States and the international community have undertaken a range of initiatives 
to address amphetamine production and trafficking. Some of the most significant ones are 
addressed below.
European initiatives
The Polish presidency of the EU (July 2011 to December 2011) has made reducing the supply of 
synthetic drugs in Europe one of its priorities. The Horizontal Working Party on Drugs (HDG) and 
the Internal Security Committee (COSI) of the Council of the EU deal with this in parallel. An 
important initiative of the Polish presidency in this respect is the development and adoption in late 
2011 of the pact against synthetic drugs. The pact is an integral part of the EU Drug Strategy 
2005–12 and EU Drug Action Plan 2009–12 and it is a practical application of the Stockholm 
Programme and of the EU Internal Security Strategy adopted by the Council in 2010. Among other 
measures, the pact targets the illicit production and trafficking of synthetic drugs such as 
amphetamine through a number of concrete measures. Europol is given a central office function for 
the coordination of the European fight against synthetic drugs. Information gathering and analysis 
will be enhanced in order to improve understanding and monitoring of production and trafficking in 
synthetic drugs and precursor chemicals in Europe. Information sharing among Member States is 
encouraged. Specialised training will be provided to European law enforcement organisations with 
a view to making the investigation and dismantling of illicit drug production facilities safer and 
more uniform at EU level. Actions implemented under the pact will be monitored by the Member 
States with assistance of the information and analysis provided by the EMCDDA and Europol. 
Project SYNERGY, including a dedicated Analysis Work File (AWF), was set up by Europol and EU 
Member States and focuses on illicit synthetic drugs in Europe. It gathers and exploits relevant 
information available within and outside the EU in order to detect links between different cases, 
identify new criminal targets and target groups. It also initiates, provides support for and coordinates 
the intelligence aspects of on-going investigations, while enhancing information exchange, 
knowledge and experience in the area of synthetic drugs, related precursors and equipment. 
The AWF currently comprises 22 participating EU Member States — Belgium, the Czech Republic, 
Denmark, Germany, Estonia, Ireland, Greece, Spain, France, Italy, Cyprus, Latvia, Lithuania, 
Hungary, the Netherlands, Austria, Poland, Portugal, Slovakia, Finland, Sweden and the United 
Kingdom — and five associated parties — Australia, Canada, Eurojust, Iceland and the United 
States. Norway and Switzerland have been invited to become associated. 
Project SYNERGY also includes the Europol Illicit Laboratory Comparison System (EILCS) and the 
Europol Ecstasy Logo System (EELS), the latter incorporated within the general Europol Synthetic 
Drug System (ESDS). The EILCS collates detailed photographic and technical information on 
synthetic drug production, storage and dump sites, thereby enabling the identification of matches 
between seized equipment, materials and chemicals, initiating information exchange, backtracking 
investigations and forensic examination for the targeting of facilitators and criminal groups. The 
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ESDS collates modus operandi, photographic and basic forensic information on significant seizures, 
enabling the identification of matches between seizures or seized punches, initiating information 
exchange, further investigations and forensic profiling for the targeting of criminal groups. Related 
criminal data arising from the findings of the ESDS and EILCS may be analysed within the AWF 
component. Furthermore, Europol specialists provide ‘on-the-spot’ assistance to Member States in 
the dismantling of illicit synthetic drug production sites.
Project SYNERGY supports, and is supported by, EU initiatives on the forensic profiling of synthetic 
drugs and related precursors for law enforcement purposes (e.g. EDPS — the European Drug 
Profiling System Project), whereby significant seizures may be forensically matched, leading to or 
supporting on-going intelligence analysis. Project CHAIN, an EU forensic and law enforcement 
initiative on the profiling of amphetamine formed in 2008, is part of an intermediate solution for 
forensic analysis of EU amphetamine samples using harmonised methodology. Amphetamine 
profiling is now a shared activity between 11 European countries (9). Profiling results are stored in a 
common database. In addition, project CHAIN developed the concept for a long-term solution at 
EU level for the use of synthetic drug forensic profiling results for law enforcement, strategic and 
operational purposes.
The EDPS, which began in February 2010, is a law enforcement-driven 3-year project which aims, 
in line with the EU Drug Action Plan 2009–12 (10), to implement an EU-wide system for the profiling 
of all synthetic and potentially other drugs, drawing on the experience gained through Europol 
project SYNERGY and project CHAIN.
The EDPS will focus on continued involvement in profiling of amphetamine, implementation of forensic 
profiling of MDMA and a feasibility study on forensic profiling of heroin and cocaine. Its specific 
objective is the targeting of organised crime involvement in the production and trafficking of illicit 
drugs by integrating forensic profiling in intelligence-led law enforcement operations. The project is 
coordinated by the Netherlands. The consortium consists of eight law enforcement agencies, 
including Europol, and seven forensic laboratories from six Member States (Belgium, Finland, France, 
the Netherlands, Sweden and the United Kingdom) and one third party (Switzerland). 
In line with the Council Conclusion on a European system for forensic drug profiling (11), Europol is 
expected to take a leading advisory role in migrating the current EDPS project to a European Union 
Drug Profiling Database (EUDPD) in 2012 and to take the measures necessary to enable it to host 
the EUDPD, within the existing Europol structure and subject to available resources. 
Mutual support also exists between the COSPOL initiative in the field of synthetic drugs and Project 
SYNERGY. The COSPOL synthetic drug group comprises Belgium (co-driver), Finland, France, 
Germany, Italy, Lithuania, the Netherlands (driver), Poland, Spain, Sweden, the United Kingdom, 
Europol and Interpol.
 (9)  Accredited forensic institutes of Belgium, Denmark, Germany, Estonia, France, the Netherlands, Norway, Poland, 
Finland, Sweden and the United Kingdom are able to perform amphetamine profiling for law enforcement 
purposes.
(10) Official Journal of the European Union 2008/C 326/09.
(11) Doc 15876/09 ENFOPOL 288/CORDROGUE 72, November 2009.
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International initiatives
The Global Synthetics Monitoring: Analyses, Reporting and Trends (SMART) programme was 
launched by the UNODC in September 2008 in Bangkok, Thailand. It aims to assist United Nations 
Member States in generating, analysing and using synthetic drug information in order to design 
effective policies and interventions. The SMART programme aims to provide information on the 
patterns of trafficking and use of synthetic drugs, including amphetamine, by supporting countries to 
better monitor trends, including detecting and reporting on new trends, while improving methods 
for exchanging comparable information (12).
Between July 2009 and March 2010, the INCB launched Operation Pila in the framework of 
Project Prism, which monitors global trade in key amphetamine precursors BMK and phenylacetic 
acid, and methamphetamine precursors ephedrine and pseudoephedrine. Operation Pila was 
intended to generate intelligence on precursor trafficking and identify weaknesses in mechanisms 
for precursor control at national and regional levels. Operation Pila led to the suspension of 40 
suspicious shipments of ephedrine and pseudoephedrine, totalling 12.8 tonnes and 199 million 
tablets. It also resulted in the identification of a number of suspicious BMK shipments. In addition, 
information gathered through Operation Pila indicated that traffickers were increasingly using 
substances not under international control, including esters of phenylacetic acid.
(12)  The EMCDDA is a member of the SMART programme steering group, and Europol closely cooperates with the 
SMART programme.
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Conclusions
As a stimulant drug, amphetamine should be considered in the context of the overall European 
market for stimulants. This encompasses a fairly large variety of European-made and imported 
drugs, some of which are based on plants, such as cocaine, and others which are purely synthetic, 
such as ecstasy (MDMA) and methamphetamine (EMCDDA, 2009b), as well as a number of other 
substances of diverse chemical make-up and changing legal status, such as piperazines (e.g. BZP) 
and synthetic cathinones (e.g. mephedrone). A significant proportion of stimulant use occurs in 
nightlife settings, which are subject to frequent changes, with shifts in the popularity of different 
drugs, and prone to innovation, with new substances emerging frequently.
In this respect, an important question raised implicitly in the present publication is the extent, and 
the terms, of the competition between amphetamine and cocaine on the European market. Will the 
strong rise in cocaine use and trafficking seen in western Europe in recent years (EMCDDA, 2010c) 
extend to other regions of the continent and, in the coming years, result in cocaine displacing 
amphetamine as the stimulant of choice in northern and central Europe, for instance? 
Several factors should be taken into account when attempting to answer this question. First, 
amphetamine is neatly a European drug, as Europe is both one of the main manufacturers of 
amphetamine in the world, perhaps even the main global producer, and a major consumer market 
for the drug. A proportion of the amphetamine manufactured in Europe is consumed locally while 
some is exported abroad, especially to the Middle East and the Arabian Peninsula. 
That said, the second factor is that patterns of amphetamine production and trafficking are not uniform 
across Europe. Improving understanding of these patterns, including how and why they may be 
changing, is clearly an important task, and one that requires more information. Four distinct 
production and trafficking areas are outlined in this publication, which partly overlap with the three 
geographical consumption areas also described here. As is the case with other drugs, history may be 
important in accounting for the emergence of several of Europe’s amphetamine production regions. 
Yet signs of change are also noticeable. In the north-west hub, Europe’s largest source of 
amphetamine, production capacity and sophistication are reported to be increasing, which could 
indicate further professionalisation of trafficking networks and the availability of large consumer 
markets. However, this sits oddly with the fact that, based on available information, overall 
amphetamine use is stabilising whereas cocaine use is increasing in Europe. Meanwhile, 
production of captagon could be moving out of south-eastern Europe and relocating closer to the 
drug’s consumer markets in the Arabian Peninsula and the Middle East. Within the dynamic 
north-east hub, amphetamine production capacity is reported to be on the rise in Poland, whereas 
in Lithuania and, to a lesser extent, Estonia, traffickers appear to have switched to producing 
methamphetamine, which now appears to be the dominant product in key consumer markets such 
as Norway and perhaps Sweden (EMCDDA, 2009b). These markets were previously supplied with 
amphetamine, mostly sourced in the Netherlands and Poland, and more information is needed to 
understand how apparent newcomers producing methamphetamine mainly out of Lithuania 
succeeded in capturing, although perhaps only temporarily, such large shares of wealthy 
Scandinavian markets from established Dutch and Polish producers. 
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Third, the European amphetamine use scene is also a diverse phenomenon. Broadly speaking, it 
involves two very different types of scene and population: a vast recreational scene mostly 
populated by socially integrated users and a much more limited marginalised scene inhabited by 
problem users. Although cocaine, especially in crack form, is also used by some marginalised 
users, it seems that cocaine use in Europe still mostly takes place in recreational settings or for 
recreational purposes. Clearly, the greatest ‘competition’ between amphetamine and cocaine, and 
thus the highest stakes, is to be found in recreational markets, where price, as well as status, is 
likely to be an important factor. Amphetamine has been, and continues to be, a much cheaper drug 
than cocaine, but with this comes lower status, with amphetamine often seen as a ‘poor man’s 
cocaine’ associated more with farmlands than the glittering lights of trendy downtown clubs. 
However, in times of recession such as the present, price concerns may override status concerns, 
especially among young users in the less affluent central and eastern parts of Europe, where 
amphetamine is already the stimulant of choice.
Our understanding of amphetamine production and trafficking in Europe is still limited. Additional 
or better-developed information systems are needed. In particular, there is a need to be able to 
estimate how much amphetamine European markets may be consuming. There is also a need to 
estimate the potential size of the production of amphetamine worldwide, and in particular within 
Europe, although progress in this area is likely to be hampered by the current lack of solid data.
For a variety of reasons, it is difficult to draw a clear picture of amphetamine supply and trafficking 
in Europe, based on traditional quantitative indicators such as seizures, prices and purity data. 
Indeed, these need to be developed further so that comparability and reliability issues can be 
addressed and more detailed data may be analysed. There is, in particular, a strong need to 
streamline the reporting of amphetamine seizures across supranational reporting systems as 
divergences seem to be greater than for other illicit drugs. In this regard, it is important that 
countries report both the quantities of amphetamine seized and the number of seizures made on a 
routine basis. The fact that amphetamine is marketed in different forms (powder, tablets, liquid) is a 
challenge for monitoring systems as they need to be able to pick up trends on all fronts. The need to 
distinguish between amphetamine and methamphetamine requires further emphasis at international 
level, in order to obtain a more accurate picture of the global context in which amphetamine 
European markets are set. Furthermore, there is a need to develop innovative alternative monitoring 
strategies that may be based on sources complementary to law enforcement, and which may rely 
on more qualitative data, with a view to better understand intra-European amphetamines markets, 
focusing especially on their structure, organisation, actors and dynamics.
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